ADAMTS13 exerts a thrombolytic effect in microcirculation

Thrombosis and Haemostasis

Volumn 108, Issue 3, 2012, Pages 527-532

  Crescente, Marilena ^a,b   Thomas, Grace M ^a,b   Demers, Melanie ^a,b   Voorhees, Jaymie R ^a   Wong, Siu Ling ^a,b   Ho Tin Noe, Benoit ^c,d   Wagner, Denisa D ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d BICHAT HOSPITAL   (France)

Author keywords

ADAMS ADAMTS 13; Intravital microscopy; Plasminogen activators; Thrombolysis thrombolytic agents

Indexed keywords

ALTEPLASE; RECOMBINANT HIRUDIN; RECOMBINANT VON WILLEBRAND FACTOR CLEAVING PROTEINASE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BLOOD FLOW; CONTROLLED STUDY; INCIDENCE; MALE; MICROCIRCULATION; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOSIS; THROMBUS;

ADAM PROTEINS; ANIMALS; CHLORIDES; COMPUTER SYSTEMS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FERRIC COMPOUNDS; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICROCIRCULATION; MICROSCOPY; RECOMBINANT PROTEINS; SKIN WINDOW TECHNIQUE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; VENOUS THROMBOSIS; VENULES;

EID: 84865817407     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-01-0046     Document Type: Article

References (38)

1. Marder VJ. Foundations of thrombolytic therapy. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. Lippincott, Williams & Wilkins 2006; pp. 1739-1752.
2. Collen D, Lijnen HR. Thrombolytic agents. Thromb Haemost 2005; 93:627-630.
3. 1 (FTT) Collaborative Group. Indications for fibri-nolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-322.
4. Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous al-teplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375:1695-1703.
5. Wechsler LR. Intravenous thrombolytic therapy for acute ischemic stroke. N Engl IMed 2011;364:2138-2146.
6. Marder VJ. Historical perspective and future direction of thrombolysis research: there-discovery of plasmin. J Thromb Haemost 2011; 9 (Suppl 1): 364-373.
7. Brill A, Fuchs TA, Chauhan AK, et al. von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood 2011; 117: 1400-1407.
8. De Meyer SF, Schwarz T, Deckmyn H, et al. Binding of von Willebrand factor to collagen and glycoprotein Ibalpha, but not to glycoprotein Ilb/IIIa, contributes to ischemic stroke in mice-brief report. Arterioscler Thromb Vase Biol 2010; 30: 1949-1951.
9. Ruggeri ZM. The role of von Willebrand factor in thrombus formation. Thromb Res 2007; 120 (Suppl l):S5-9.
10. Ni H, Denis CV, Subbarao S, et al. Persistence of platelet thrombus formation in arterioles of mice lackingboth von Willebrand factor and fibrinogen. J Clin Invest 2000; 106: 385-392.
11. Plaimauer B, Zimmermann K, Volkel D, et al. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood 2002; 100: 3626-3632.
12. Chauhan AK, Motto DG, Lamb CB, et al. Systemic antithrombotic effects of ADAMTS13. J Exp Med 2006; 203: 767-776.
13. Zhao BQ, Chauhan AK, Canault M, et al. von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. Blood 2009; 114:3329-3334.
14. Boulaftali Y, Ho-Tin-Noe B, Pena A, et al. Platelet protease nexin-1, a serpin that strongly influences fibrinolysis and thrombolysis. Circulation 2011; 123: 1326-1334.
15. Lehr HA, Leunig M, Menger MD, et al. Dorsal skinfold chamber technique for in-travital microscopy in nude mice. Am J Pathol 1993; 143:1055-1062.
16. Boulaftali Y, Lamrani L, Rouzaud MC, et al. The mouse dorsal skinfold chamber as a model for the study of thrombolysis by intravital microscopy. Thromb Haemost 2012; 107: 962-971.
17. Thomas GM, Panicot-Dubois L, Lacroix R, et al. Cancer cell-derived micropar-ticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J Exp Med 2009; 206: 1913-1927.
18. Dubois C, Atkinson B, Furie BC, et al. Real-time in vivo imaging of platelets during thrombus formation. In: Platelets. Elsevier/Academic Press 2006; pp. 611-628.
19. Yamamoto J, Kawano M, Hashimoto M, et al. Adjuvant effect of antibodies against von Willebrand Factor, fibrinogen, and fibronectin on staphylokinase-induced thrombolysis as measured using mural thrombi formed in rat mesenteric venules. Thromb Res 2000; 97: 327-333.
20. Gurevitz O, Goldfarb A, Hod H, et al. Recombinant von Willebrand factor fragment AR545C inhibits platelet aggregation and enhances thrombolysis with rtPA in a rabbit thrombosis model. Arterioscler Thromb Vase Biol 1998; 18:200-207.
21. Mazighi M, Serfaty JM, Labreuche J, et al. Comparison of intravenous alteplase with a combined intravenous-endovascular approach in patients with stroke and confirmed arterial occlusion (RECANALISE study): a prospective cohort study. Lancet Neurol 2009; 8: 802-809.
22. Ouriel K. Current status of thrombolysis for peripheral arterial occlusive disease. Ann Vase Surg 2002; 16: 797-804.
23. Alesh I, Kayali F, Stein PD. Catheter-directed thrombolysis (intrathrombus injection) in treatment of deep venous thrombosis: a systematic review. Catheter Car-diovasclnterv 2007; 70: 143-148.
24. Kim HS, Preece SR, Black JH, et al. Safety of catheter-directed thrombolysis for deep venous thrombosis in cancer patients. J Vase Surg 2008; 47: 388-394.
25. Mewissen MW, Seabrook GR, Meissner MH, et al. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry. Radiology 1999; 211: 39-49.
26. Kuo WT, van den Bosch MA, Hofmann LV, et al. Catheter-directed embolectomy, fragmentation, and thrombolysis for the treatment of massive pulmonary embolism after failure of systemic thrombolysis. Chest 2008; 134: 250-254.
27. Kuo WT, Gould MK, Louie JD, et al. Catheter-directed therapy for the treatment of massive pulmonary embolism: systematic review and meta-analysis of modern techniques. JVasc IntervRadiol 2009; 20:1431-1440.
28. Korninger C, Collen D. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemost 1981; 46: 561-565.
29. Lijnen HR, van Hoef B, Beelen V, et al. Characterization of the murine plasma fibrinolytic system. Eur J Biochem 1994; 224: 863-871.
30. Zhu Y, Carmeliet P, Fay WR Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation 1999; 99: 3050-3055.
31. Kilic E, Hermann DM, Hossmann KA. Recombinant tissue-plasminogen activator-induced thrombolysis after cerebral thromboembolism in mice. Acta Neur-opathol 2000; 99: 219-222.
32. Orset C, Macrez R, Young AR, et al. Mouse model of in situ thromboembolic stroke and reperfusion. Stroke 2007; 38:2771-2778.
33. Lapergue B, Moreno JA, Dang BQ, et al. Protective effect of high-density lipopro-tein-based therapy in a model of embolic stroke. Stroke 2010; 41:1536-1542.
34. Grines CL, Serruys P, O'Neill WW. Fibrinolytic therapy: is it a treatment of the past? Circulation 2003; 107: 2538-2542.
35. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008; 372: 1303-1309.
36. Westerhout CM, Bonnefoy E, Welsh RC, et al. The influence of time from symptom onset and reperfusion strategy on 1 -year survival in ST-elevation myocardial infarction: a pooled analysis of an early fibrinolytic strategy versus primary percutaneous coronary intervention from CAPTIM and WEST. Am Heart J 2011; 161:283-290.
37. Crawley JT, de Groot R, Xiang Y, et al. Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor. Blood 2011; 118: 3212-3221.
38. Jin R, Yang G, Li G. Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiol Dis 2010; 38: 376-385.